A pharmacological surveillance study of the tolerability of policosanol in the elderly population

Lipid Research Clinics Program, 1984, The Lipid Research Clinics coronary primary prevention trial results. II. The relationship on reduction in the incidence of coronary heart disease to cholesterol lowering, JAMA, 251, 365, 10.1001/jama.1984.03340270043026 1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S), Lancet, 344, 1383 Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, N Engl J Med, 335, 1001, 10.1056/NEJM199610033351401 1998, Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N Engl J Med, 339, 1349, 10.1056/NEJM199811053391902 Shepherd, 1995, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia, N Engl J Med, 333, 1301, 10.1056/NEJM199511163332001 Downs, 1998, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS, JAMA, 279, 1615, 10.1001/jama.279.20.1615 2002, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial, Lancet, 360, 7, 10.1016/S0140-6736(02)09327-3 Shepherd, 2002, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomized controlled study, Lancet, 360, 1623, 10.1016/S0140-6736(02)11600-X Manolio, 1992, Cholesterol and heart disease in older persons and women: Review of an NHLBI workshop, Ann Epidemiol., 2, 161, 10.1016/1047-2797(92)90051-Q Bilheimer, 1991, Clinical considerations regarding treatment of hypercholesterolemia in the elderly, Atherosclerosis, 91, S35, 10.1016/0021-9150(91)90205-H Más, 2000, Policosanol, Drugs Future, 25, 569, 10.1358/dof.2000.025.06.574693 Menéndez, 1994, Policosanol inhibits cholesterol biosynthesis and enhances LDL processing in cultured human fibroblasts, Biol Res., 27, 199 Menéndez, 1996, Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolemia induced by a wheat starch-casein diet, Brit J Nutr., 77, 923, 10.1079/BJN19970090 Menéndez, 2001, Policosanol modulates HMGCoA reductase activity in cultured fibroblasts, Arch Med Res., 32, 8, 10.1016/S0188-4409(00)00265-4 Hernández, 1992, Effects of policosanol on serum lipids and lipoproteins in healthy volunteers, Curr Ther Res Clin Exp, 51, 568 Pons, 1994, Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment, Int J Clin Pharmacol Res., 14, 27 Más, 1999, Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors, Clin Pharmacol Ther., 65, 439, 10.1016/S0009-9236(99)70139-6 Castaño, 2000, Effect of policosanol on postmenopausal women with type II hypercholesterolemia, Gynecol Endocrinol, 13, 1 Castaño, 1999, Effects of policosanol, pravastation on lipid profile, platelet aggregation, endothelemia in older hypercholesterolemic patients, Int Clin Pharm Res., 19, 105 Fernández, 2001, Comparison of the efficacy, safety and tolerability of policosanol versus fluvastatin in elderly hypercholesterolemic women, Clin Invest., 21, 103 Castaño, 2001, Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk, J Gerontol A., 56, M186, 10.1093/gerona/56.3.M186 Más, 2001, Effects of policosanol in older hypercholesterolemic patients with coronary disease, Clin Drug Invest., 21, 485, 10.2165/00044011-200121070-00004 Castaño, 2002, Comparison of the efficacy, safety and tolerability of policosanol versus atorvastatin in elderly patients with type II hypercholesterolemia, Drugs Aging, 20, 153, 10.2165/00002512-200320020-00006 Más, 2002, Effects of policosanol on morbidity and mortality in older hypercholesterolemic patients, J Am Coll Cardiol., 39, 429B Torres, 1995, Treatment of hypercholesterolemia in NIDDM with policosanol, Diabetes Care, 18, 393, 10.2337/diacare.18.3.393 Crespo, 1999, Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus, Int J Clin Pharmacol Res., 19, 117 Castaño, 2003, Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidemia and type 2 diabetes mellitus, Clin Drug Invest., 23, 639, 10.2165/00044011-200323100-00003 Arruzazabala, 1993, Effect of policosanol on cerebral ischemia in mongolian gerbils: Role of prostacyclin and thromboxane A2, Prostaglandins Leukot Essent Fatty Acids, 49, 695, 10.1016/0952-3278(93)90080-G Arruzazabala, 1996, Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers, Pharmacol Res., 34, 181, 10.1006/phrs.1996.0086 Carbajal, 1998, Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers, Prostaglandins Leukot Essent Fatty Acids, 58, 61, 10.1016/S0952-3278(98)90130-2 Arruzazabala, 1998, Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients, Int J Tissue React, 10, 119 Alemán, 1992, Acute, subchronic and chronic toxicology of policosanol in rats, Toxicol Lett., 248 Mesa, 1994, Toxicity of policosanol in beagledogs: One year study, Toxicol Lett., 73, 81, 10.1016/0378-4274(94)90098-1 Alemán, 1994, A 12-month study of policosanol oral toxicity in Sprague-Dawley rats, Toxicol Lett., 70, 77, 10.1016/0378-4274(94)90147-3 Alemán, 1994, Carcinogenicity of policosanol in Sprague Dawley rats: A 24 month study, Teratog Carcinog Mutagen., 14, 239, 10.1002/tcm.1770140505 Rodríguez, 1994, Teratogenic and reproductive studies of policosanol in the rat and rabbit, Teratog Carcinog Mutagen, 14, 107, 10.1002/tcm.1770140302 Fernández, 1998, Policosanol: Results of a postmarketing surveillance control on 27 879 cases, Curr Ther Res Clin Exp., 59, 717, 10.1016/S0011-393X(98)85030-3 Más, 1999, Pharmacoepidemiologic study of policosanol, Curr Ther Res Clin Exp., 60, 458, 10.1016/S0011-393X(99)80024-1 Naranjo, 1981, A method for estimating the probability of adverse drug reactions, Clin Pharmacol Ther., 30, 239, 10.1038/clpt.1981.154 Baker, 2001, Statin myopathies: Pathophysiologic and clinical perspectives, Clin Invest Med., 24, 258 Gaist, 2001, Lipid-lowering drugs and risk of myopathy: A population-based followup study, Epidemiology, 12, 565, 10.1097/00001648-200109000-00017 Pasternak, 2002, ACC/AHA/NHLBI Clinical Advisory on the use and safety of statins, J Am Coll Cardiol, 40, 567, 10.1016/S0735-1097(02)02030-2 Zardoya, 1996, Effects of policosanol on hypercholesterolemic patients with disturbances on serum biochemical indicators of hepatic function, Curr Ther Res Clin Exp., 57, 568, 10.1016/S0011-393X(96)80068-3 Snider, 1984, Octacosanol in parkinsonism, Ann Neurol., 16, 723, 10.1002/ana.410160615